Rhinoconjunctivitis Clinical Trial
Official title:
An Optional Investigation of Biomarkers of Efficacy in TH002 Clinical Study Subjects.
House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and
fabric. Like many other allergens, exposure to HDMA in sensitised patients is associated
with poorer lung function, greater medication requirements and more asthma symptoms as well
as chronic rhinosinusitis symptoms. In contrast to other allergens, there is evidence that
HDMA leads to the development of asthma, in addition to exacerbating pre-existing asthma in
HDM-sensitised patients.
ToleroMune House Dust Mite (TM-HDM) is being developed for the treatment of HDM allergy.
Study TH002 evaluated the efficacy, safety and tolerability of TM-HDM. This study will
identify cellular, proteomic or genetic biomarkers of efficacy to TM-HDM treatment in TH002
study participants
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05560698 -
A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
|
N/A | |
| Completed |
NCT02849210 -
A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea
|
Phase 1 | |
| Completed |
NCT02150343 -
Phase II HDM-SPIRE Safety and Efficacy Study
|
Phase 2 | |
| Completed |
NCT02340130 -
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
|
Phase 2 | |
| Completed |
NCT01949441 -
ToleroMune House Dust Mite (HDM) Tolerability Study
|
Phase 2 | |
| Completed |
NCT01949428 -
House Dust Mite Observational Study
|
N/A | |
| Completed |
NCT01923792 -
ToleroMune House Dust Mite Follow on Study
|
N/A | |
| Completed |
NCT01447784 -
ToleroMune House Dust Mites (HDM) Exposure Chamber Study
|
Phase 2 | |
| Recruiting |
NCT04435990 -
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
|
Phase 3 | |
| Recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
| Completed |
NCT01720251 -
Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
|
Phase 2 | |
| Completed |
NCT01620762 -
Phase III Cat-PAD Study
|
Phase 3 | |
| Completed |
NCT01448603 -
ToleroMune Ragweed Follow up Study
|
N/A | |
| Completed |
NCT01353755 -
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
|
Phase 3 | |
| Completed |
NCT00537342 -
Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)
|
Phase 3 | |
| Completed |
NCT00540631 -
Multicenter Trial of Immunotherapy With House Dust Mite Allergoid
|
Phase 3 | |
| Completed |
NCT00574210 -
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
|
Phase 2 | |
| Completed |
NCT05540717 -
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
|
Phase 3 | |
| Completed |
NCT02844842 -
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
|
||
| Completed |
NCT01734265 -
Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).
|
Phase 2 |